论文部分内容阅读
目的观察急性髓性白血病(AML)缓解后应用大剂量阿糖胞苷(HD-Ara-C)联合常规化疗治疗的疗效。方法将29例AML患者随机分为治疗组和对照组。治疗组15例患者在常规化疗基础上第1、3、5d用HD-Ara-C持续3h以上静脉滴注,1~2次/年。对照组患者行常规化疗。比较两组患者治疗后1年、3年和5年的无病生存(DFS)情况。结果两组患者治疗后1年、3年和5年的DFS情况间差别均有显著性意义(P<0·01)。结论HD-Ara-C用于AML缓解后的维持强化治疗疗效较好,可延长患者的DFS期。
Objective To observe the effect of high-dose cytarabine (HD-Ara-C) combined with conventional chemotherapy in the treatment of acute myeloid leukemia (AML). Methods 29 AML patients were randomly divided into treatment group and control group. In the treatment group, 15 patients were treated with HD-Ara-C for more than 3 h on the first, third, fifth day after conventional chemotherapy, once or twice a year. Control group patients underwent routine chemotherapy. Disease-free survival (DFS) at 1, 3, and 5 years after treatment was compared between the two groups. Results The differences of DFS between 1, 3 and 5 years after treatment in both groups were significant (P <0.01). Conclusion HD-Ara-C is effective in maintaining intensive therapy after remission of AML, and can prolong the DFS of patients.